RECORDATI: I RISULTATI POSITIVI DELLO STUDIO DI FASE III LINC-4 PRESENTATI AL CONGRESSO ANNUALE DELLA ENDOCRINE SOCIETY RICONFERMANO L’EFFICACIA E LA SICUREZZA DI ISTURISA® (OSILODROSTAT) PER IL TRATTAMENTO DELLA MALATTIA DI CUSHING

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

Paul Theisen
Patient Acquisition

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Amy Giles
Increasing Engagement

Matt Turner
Patient Affordability

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Matthew Durham
Omnidynamic Marketing

David Linetsky
Point-of-Care Marketing

Bud Bilanich
Success Coach